Given the hoopla surrounding data for Plexxikon Inc.'s targeted melanoma candidate Zelboraf (vemurafenib) earlier this year, a sooner-than-expected FDA nod for the drug and its companion diagnostic in patients with a specific BRAF mutation came as little surprise.